Fulcrum Therapeutics (FULC) Cash & Equivalents: 2019-2025
Historic Cash & Equivalents for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $200.6 million.
- Fulcrum Therapeutics' Cash & Equivalents rose 176.26% to $200.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.6 million, marking a year-over-year increase of 176.26%. This contributed to the annual value of $241.0 million for FY2024, which is 2.03% up from last year.
- According to the latest figures from Q3 2025, Fulcrum Therapeutics' Cash & Equivalents is $200.6 million, which was down 6.29% from $214.1 million recorded in Q2 2025.
- Over the past 5 years, Fulcrum Therapeutics' Cash & Equivalents peaked at $241.0 million during Q4 2024, and registered a low of $30.1 million during Q3 2023.
- In the last 3 years, Fulcrum Therapeutics' Cash & Equivalents had a median value of $86.7 million in 2024 and averaged $128.8 million.
- In the last 5 years, Fulcrum Therapeutics' Cash & Equivalents slumped by 66.93% in 2022 and then spiked by 573.03% in 2023.
- Fulcrum Therapeutics' Cash & Equivalents (Quarterly) stood at $35.4 million in 2021, then dropped by 0.89% to $35.1 million in 2022, then soared by 573.03% to $236.2 million in 2023, then increased by 2.03% to $241.0 million in 2024, then soared by 176.26% to $200.6 million in 2025.
- Its Cash & Equivalents was $200.6 million in Q3 2025, compared to $214.1 million in Q2 2025 and $226.6 million in Q1 2025.